| Previous close | 1,575.00 |
| Open | 1,565.00 |
| Bid | 1,595.00 x 0 |
| Ask | 1,600.00 x 0 |
| Day's range | 1,525.00 - 1,625.00 |
| 52-week range | 1,080.00 - 4,500.00 |
| Volume | 34,342,300 |
| Avg. volume | 22,583,908 |
| Market cap | 4.329T |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | 5.81 |
| EPS (TTM) | 275.42 |
| Earnings date | 15 Jun 2020 - 19 Jun 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 08 May 2019 |
| 1y target est | 9,175.50 |
* Thailand posts best intraday session since April 20 * Vietnam extends gains into fifth session * Malaysian markets closed for a public holiday By Pranav A K May 11 (Reuters) - Southeast Asian stock markets closed higher on Monday, with Vietnam leading gains, as several countries looked to restart their economies and largest regional trading partner China signaled more policy measures to support a virus-hit economy. The People's Bank of China (PBOC) vowed on Sunday it would step up counter-cyclical adjustments to support the Chinese economy and make monetary policy more flexible to fend off financial risks, and said it lowered interest rates on its standing lending facility (SLF) in April. "We think the bar for large further rate cuts, particularly in short-end rates, is high in China," analysts at Goldman Sachs said in a note.
* Philippines posts biggest weekly fall since March 20 * Malaysia, Indonesia, Philippines extend restrictions By Nikhil Subba April 24 (Reuters) - Most Southeast Asian stock markets ended lower on Friday, logging weekly losses, as governments in the region extended lockdowns and a report raised concerns about progress in developing a treatment for COVID-19. Gilead Sciences Inc's experimental coronavirus drug, remdesivir, failed its first randomized clinical trial, according to a report on Thursday, hammering risk sentiment globally. Gilead said the findings were inconclusive because the study conducted in China was terminated early.